



New Results

[Follow this preprint](#)

The ER tether VAPA is required for proper cell motility and anchors ER-PM contact sites to focal adhesions

Hugo Siegfried, Rémi Le Borgne, Catherine Durieu, Thaïs De Azevedo Laplace, Agathe Verraes, Lucien Daunas, Jean-Marc Verbavatz, Mélina L. Heuzé

doi: <https://doi.org/10.1101/2022.10.17.512434>

This is a preprint. It has not been certified by a journal but peer reviews are available. [what does this mean?].



[Abstract](#)

[Full Text](#)

[Info/History](#)

[Metrics](#)

[Preview PDF](#)

ABSTRACT

Cell motility processes highly depend on the membrane distribution of Phosphoinositides (PI_nst), giving rise to cytoskeleton reshaping and membrane trafficking events. Membrane contact sites serve as platforms for lipid exchange and calcium fluxes between two organelles. Here, we show that VAPA, an ER membrane-resident contact site tether, plays a crucial role during cell motility. CaCo2 adenocarcinoma epithelial cells depleted for VAPA exhibit several collective and individual motility defects, disorganized actin cytoskeleton and altered protrusive activity. During migration, VAPA is required for the maintenance of PI(4,5)P₂ levels at the plasma membrane, but not for PI(4)P homeostasis in the Golgi and endosomal compartments. Importantly, we show that VAPA regulates the dynamics of focal adhesions (FA) through its MSP domain, and is essential to stabilize and anchor ventral ER-PM contact sites to FA, thus mediating microtubule-dependent FA disassembly. To conclude, our results reveal unprecedented functions for VAPA-mediated membrane contact sites during cell motility and provides a dynamic picture of ER-PM contact sites connection with FA mediated by VAPA.

Competing Interest Statement

The authors have declared no competing interest.

Copyright

The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[^ Back to top](#)[← Previous](#)[Next →](#)

Posted January 10, 2023.

[📄 Download PDF](#)[✉ Email](#)[☑ Print/Save Options](#)[↪ Share](#)[📄 Supplementary Material](#)[🌐 Citation Tools](#)[✍ Revision Summary](#)[Tweet](#)

COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Subject Area

[Cell Biology ▶](#)

Subject Areas

All Articles

[Animal Behavior and Cognition](#)[Biochemistry](#)[Bioengineering](#)[Bioinformatics](#)[Biophysics](#)[Cancer Biology](#)[Cell Biology](#)[Clinical Trials*](#)[Developmental Biology](#)[Ecology](#)[Epidemiology*](#)[Evolutionary Biology](#)[Genetics](#)[Genomics](#)[Immunology](#)[Microbiology](#)[Molecular Biology](#)[Neuroscience](#)

Paleontology

Pathology

Pharmacology and Toxicology

Physiology

Plant Biology

Scientific Communication and Education

Synthetic Biology

Systems Biology

Zoology

*The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).

Supported by **Chan
Zuckerberg
Initiative** 